Table 1.
Clinical characteristics of the COVID-19 patients
| Survivor (n = 37) | Non-survivor (n = 13) | p value | |
|---|---|---|---|
| Age (years), median with (IQR) | 49 (42–66) | 72 (65–77) | < 0.001* |
| Sex, no. (%) | |||
| Female | 16 (43.2%) | 3 (22.2%) | < 0.001* |
| Male | 21 (56.8%) | 10 (77.8%) | |
| Hospitalization time | |||
| Median with (IQR) | 6 (4–8) | 12(7–21) | 0.071 |
| Serum selenium [μg/L], mean ± SD | 77. 9 ± 14.3 μg/L | 77.2 ± 12. 3 μg/L | p > .05 |
| Laboratory findings | |||
| Median with (IQR) | |||
| No. (%) | |||
| White blood cell count, × 109/L | 6.1 (4.9–7.9) | 6.2 (3.9–12.2) | 0.851 |
| < 4 | 5 (13.5%) | 3 (23.1%) | |
| 4–10 | 28 (75.6%) | 5 (38.4%) | |
| > 10 | 4 (10.9%) | 5 (38.5%) | |
| Lymphocyte count, × 109/L | 1.2 (1–1.6) | 0.9 (0.6–1.3) | 0.037 |
| < 0·8 | 3 (8.1%) | 5 (38.5%) | |
| Neutrophil count, × 109/L | 3.7 (2.6–5.4) | 4.7 (2.8–9.8) | 0.162 |
| Neutrophil‐to‐lymphocyte ratio | 2.2 (1.9–4.2) | 6.3 (4–8.2) | < 0.001* |
| Platelet count, × 109/L | 194 (141–263) | 134 (105–210) | 0.014* |
| 4 (10.8%) | 3 (23.1%) | ||
| Lactate dehydrogenase, U/L | 631 (430–797) | 993 (746–1379) | |
| > 245 | 36 (97%) | 12 (92.3%) | 0.015* |
IQR interquartile range,: number, SD standard deviation.*Significant group difference at p < 0.05. Data were expressed as median with IQR, mean ± SD, or numbers and percentages